0LW1 Stock Chart & Stats
€0.01
--
Market closed
€0.01
--
Day’s Range― - ―
52-Week Range<€0.01 - €4,010.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00
Market Cap
€163.95K
Enterprise Value€3.26B
Total Cash (Recent Filing)€571.79K
Total Debt (Recent Filing)€537.20K
Price to Earnings (P/E)―
Beta5.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,821,676
10 Day Avg. Volume4
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage gives Neovacs greater financial flexibility than a heavily indebted biotech and limits near-term refinancing pressure. This can preserve options for research investment or partnerships, although it does not by itself resolve the company’s ongoing losses or funding needs.
Kinoid Immunotherapy PlatformNeovacs has a defined technology platform aimed at generating durable immune responses in chronic inflammatory and autoimmune diseases. If development succeeds, this platform could support multiple programs or licensing opportunities rather than relying on only one potential product.
Improving Cash-Burn TrendAlthough Neovacs remains cash-flow negative, the slower burn reported in 2025 is a constructive trend for financial endurance. Sustained improvement could extend available resources and reduce the urgency of external funding, provided operating performance continues to improve.
Bears Say
Sharp Revenue DeclineThe steep 2025 revenue contraction and history of inconsistent sales indicate that Neovacs has not established a stable commercial revenue base. Weak and volatile top-line performance limits operating leverage, reduces internal funding capacity, and makes future growth dependent on successful development or partnering.
Persistent UnprofitabilityRecurring losses and negative gross profit show that current activity does not cover the company’s cost base. Without stronger revenue or lower operating expenses, continued unprofitability can erode shareholder capital and constrain investment in the Kinoid pipeline over the next several quarters.
Ongoing External Funding NeedPersistent negative operating and free cash flow means Neovacs is not self-funding its activities. Unless revenue improves materially or costs fall, the company will likely remain reliant on external capital over time, creating financial pressure and limiting strategic flexibility.
0LW1 FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was <€0.01 and its highest was €4010.00 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €163.95K.
When is Neovacs SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neovacs SA’s earnings last quarter?
Currently, no data Available
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 1,821,676 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in DE:0LW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.